Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262610 · ClinicalTrials.gov registry record · Phase 2
Setmelanotide in a Single Patient With Partial Lipodystrophy
A Phase 2 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03262610 is a Phase 2 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 1 participants.
The verdict
NCT03262610, a Phase 2 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.
Interventions
- DRUG Setmelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03262610
The ClinicalTrials.gov registry entry for NCT03262610 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhythm Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Setmelanotide is the first listed.
NCT03262610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03262610 about?
NCT03262610 is a clinical study titled "Setmelanotide in a Single Patient With Partial Lipodystrophy". The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.
What is the current status of trial NCT03262610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-08-15. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT03262610?
The interventions under investigation include: Setmelanotide (DRUG).
Who is sponsoring clinical trial NCT03262610?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.